Carlos Martín-Alonso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Martín-Alonso has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Alba Escolà-Rodríguez
Pharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain
1 shared publication - Aleix Borja Fabregat Bolufer
Biochemistry and Molecular Genetics Department, CDB, Hospital Clínic of Barcelona, Barcelona, Spain
1 shared publication - Manuel Morales-Ruiz
Biochemistry and Molecular Genetics Department, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 08036 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (6) , K21-K25
Overdiagnosed and oversupplemented: the iatrogenic rise of vitamin D toxicity
Spanish pharmacovigilance alerts have highlighted vitamin D overdosing. We retrospectively analysed adult serum 25(OH)D results from a Barcelona tertiary hospital (2020-2025), measured using a VDSCP-certified immunoassay. For results >100 ng/mL (250 nmol/L), concomitant calcium, phosphorus, albumin, alkaline phosphatase and parathyroid hormone were retrieved. Hypercalcemia was defined as albumin-corrected calcium >10.5 mg/dL. Among 185 604 results, annual testing increased by 54.1% and median 25(OH)D rose from 25.3 to 28.6 ng/mL. Very high results more than doubled (31 [0.14%] to 108 [0.31%]; n = 393). Calcium was available in 324/393 results, and hypercalcemia occurred in 14/324 (4.3%). Calcifediol was documented in 183/201 (91.0%) hypervitaminosis D patients with available supplementation data and in 12/14 (85.7%) hypercalcemic cases, often in short-interval dosing regimens. Rapid test growth paralleled a rightward shift and expanding high-concentration tail, supporting evidence-based requesting, clearer intermittent-dosing and supplementation instructions, and selective serum calcium surveillance when 25(OH)D is greatly elevated.
- 18 May 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (6) , K21-K25
Open AccessOverdiagnosed and oversupplemented: the iatrogenic rise of vitamin D toxicity
Spanish pharmacovigilance alerts have highlighted vitamin D overdosing. We retrospectively analysed adult serum 25(OH)D results from a Barcelona tertiary hospital (2020-2025), measured using a VDSCP-certified immunoassay. For results >100 ng/mL (250 nmol/L), concomitant calcium, phosphorus, albumin, alkaline phosphatase and parathyroid hormone were retrieved. Hypercalcemia was defined as albumin-corrected calcium >10.5 mg/dL. Among 185 604 results, annual testing increased by 54.1% and median 25(OH)D rose from 25.3 to 28.6 ng/mL. Very high results more than doubled (31 [0.14%] to 108 [0.31%]; n = 393). Calcium was available in 324/393 results, and hypercalcemia occurred in 14/324 (4.3%). Calcifediol was documented in 183/201 (91.0%) hypervitaminosis D patients with available supplementation data and in 12/14 (85.7%) hypercalcemic cases, often in short-interval dosing regimens. Rapid test growth paralleled a rightward shift and expanding high-concentration tail, supporting evidence-based requesting, clearer intermittent-dosing and supplementation instructions, and selective serum calcium surveillance when 25(OH)D is greatly elevated.